Human polyomavirus BKV and renal disease

Human polyomavirus BKV and renal disease.

Urinary shedding of BKV is increased in immunocomIn 1971, two human polyomaviruses were discovered, BK virus (BKV ) from the urine of a renal transplant promising conditions. BKV infection has been linked to occasional cases of cystitis in immunocompetent recipient (whose initials were B.K.) and JC virus (JCV ) from the brain of a patient (whose initials were J.C.) children, to glomerulonephrit...

Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients.

BK virus-allograft nephropathy (BKVAN) is an increasingly recognized complication after kidney transplantation. Quantitative tests have been advocated to monitor patients, but data demonstrating their efficacy are relatively limited. We developed a real-time PCR assay to quantitate BK virus loads in the setting of renal transplantation, and we correlated the BK virus load with clinical course a...

XWH - 06 - 1 - 0132 TITLE : Role of Human Polyomavirus Bkv in Prostate Cancer

Early BK polyomavirus (BKV) reactivation in donor kidney is a risk factor for development of BKV-associated nephropathy.

The pathogenesis of BK polyomavirus (BKV) infection and associated nephropathy in renal transplant recipients is not clearly understood. To gain insight, urine and plasma samples were collected from 112 renal transplant recipients before and after transplantation and tested for the presence of BKV by polymerase chain reaction. Detection of BKV infection very early (ie, 5 days) after transplanta...

BKV replication and cellular immune responses in renal transplant recipients.

Hammer and colleagues report on BKV-specific T-cell responses in peripheral blood mononuclear cells (PBMC) of 15 viremic kidney transplant recipients (1). After stimulation with overlapping peptides spanning the viral capsid protein VP1, interferon-c (IFNc )-producing CD4+ T cells were observed in 7 patients (47%), including 2 patients (13%) with a CD8+ T-cell response. All patients with a dete...